Fangsheng Pharmaceutical 方盛制药
6 significant filings since 31 May 2026: 2 on dividend, 1 on buyback and 1 on major contract or bid won, and 2 other kinds. The latest, on 7 Sep 2026: 方盛制药2026年半年度权益分派实施公告.
自 31 May 2026 起有 6 份重大公告：dividend 2 份、buyback 1 份、major contract or bid won 1 份，另有 2 类。最新一份（7 Sep 2026）：方盛制药2026年半年度权益分派实施公告。
Price History 价格走势
66 trading days 个交易日 · High 最高 ¥11.02 · Low 最低 ¥8.68The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,龙永茂 | Buy 买入 | 11 Sep 2026 | 4 | — |
| 开源证券 | 余汝意,巢舒然 | Buy 买入 | 1 Sep 2026 | 2 | — |
| 东吴证券 | 朱国广,向潇 | Buy 买入 | 31 Aug 2026 | 3 | — |
| 信达证券 | 唐爱金,章钟涛 | Unrated | 29 Apr 2026 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 11 reports. 每行为该券商近十二个月的最新研报；11 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。